Gastrointestinal (GI) cancers are cancers that develop anywhere along the digestive tract or in organs that help with digestion. Together, they account for roughly 4.7 million new cases worldwide each year, making them one of the most common and deadly groups of cancers. The five major types affect the esophagus, stomach, colon and rectum, liver, and pancreas.
The Five Major Types
Colorectal cancer is the most common GI cancer by a wide margin, with an estimated 1.8 million new cases globally in 2018 and roughly 154,270 new cases expected in the United States in 2025. Stomach cancer follows at about 1 million cases globally. Liver cancer accounts for around 840,000 cases, esophageal cancer about 570,000, and pancreatic cancer approximately 460,000.
Each of these cancers has its own risk profile, typical age of onset, and outlook, but they share the fact that early detection dramatically improves survival. Some, like colorectal cancer, have effective screening programs. Others, like pancreatic cancer, are notoriously difficult to catch early.
Colorectal Cancer
Colorectal cancer starts in the colon or rectum, often beginning as small growths called polyps that slowly become cancerous over years. This slow progression is exactly why screening works so well. The U.S. Preventive Services Task Force recommends screening beginning at age 45 and continuing through age 75.
Several screening options exist. A colonoscopy is done every 10 years for people at average risk. A stool-based test that looks for hidden blood (called a FIT test) is done yearly. A stool DNA test combines a blood-detection test with one that finds altered DNA and is done every three years. A flexible sigmoidoscopy, which examines only the lower third of the colon, is done every five years. The right choice depends on your risk level and preferences.
Physical activity is one of the strongest protective factors, reducing colorectal cancer risk by about 20% at high activity levels, with greater benefits the more active you are. Diets rich in fruits, vegetables, fiber, fish, and dairy also lower risk, while diets heavy in red and processed meat raise it. Following a Mediterranean-style diet is associated with an 8 to 17% reduction in risk. Alcohol and tobacco both increase it.
Stomach Cancer
An estimated 30,300 new cases of stomach cancer will be diagnosed in the United States in 2025, with about 10,780 deaths. The single biggest driver is chronic infection with the bacterium H. pylori, which causes long-lasting stomach inflammation. Over time, this inflammation can thin the stomach lining and eventually lead to cancer. The majority of stomach cancers are attributed to this infection.
Stomach cancer is often subtle and difficult to detect early because its symptoms overlap with common digestive complaints: feeling bloated after eating, getting full quickly, persistent heartburn or indigestion, nausea, and unexplained weight loss. Black, tarry stools can signal bleeding in the stomach. Many people have no symptoms at all in the early stages, which is part of what makes this cancer dangerous.
Upper endoscopy, where a thin, flexible camera is guided through the mouth into the stomach, is the gold standard for diagnosis. Doctors look for irregular surfaces or color changes in the stomach lining and take tissue samples from suspicious areas.
Esophageal Cancer
The esophagus, the tube connecting your throat to your stomach, can develop two main types of cancer that account for 90 to 95% of all cases. Squamous cell carcinoma, more common in parts of Asia and Africa, is linked to smoking and alcohol use. Adenocarcinoma, more common in Western countries, is driven by chronic acid reflux (GERD) and obesity. When stomach acid repeatedly washes up into the lower esophagus, it can trigger a condition called Barrett’s esophagus, which raises cancer risk.
Interestingly, H. pylori infection, despite causing stomach cancer, actually appears to protect against esophageal adenocarcinoma. The bacterium reduces stomach acid output over time, which means less acid flows back into the esophagus. Difficulty swallowing is the hallmark symptom of esophageal cancer and often the reason people seek medical attention.
Liver Cancer
About 75 to 85% of primary liver cancers are hepatocellular carcinoma, which typically develops in people who already have chronic liver disease. The underlying cause varies by geography. In Asia and Africa, chronic hepatitis B infection is the leading driver. In North America, Europe, and Japan, chronic hepatitis C is the primary cause.
Cirrhosis, the replacement of healthy liver tissue with scar tissue, is the common thread. Chronic alcoholism and chronic hepatitis infections are the most frequent causes of cirrhosis. People with cirrhosis from hepatitis C face a higher liver cancer risk than those with cirrhosis from hepatitis B or alcohol. Vaccination against hepatitis B and treatment of hepatitis C are two of the most effective preventive measures for liver cancer worldwide.
Pancreatic Cancer
Pancreatic cancer has the grimmest outlook of any major GI cancer, with a five-year survival rate below 10%. An estimated 67,440 new cases will be diagnosed in the U.S. in 2025, with nearly as many deaths: 51,980. The pancreas sits deep in the abdomen, and tumors there rarely cause noticeable symptoms until the disease has spread.
Smoking is the most established risk factor, responsible for roughly 20 to 25% of cases. Smokers are twice as likely to develop pancreatic cancer, and the elevated risk persists for up to 20 years after quitting. Obesity raises risk by about 20%. Long-standing type 2 diabetes increases risk by 50 to 100% compared to people without diabetes. About 10% of cases are hereditary, linked to mutations in genes like BRCA1 and BRCA2. People with hereditary pancreatitis, a rare genetic condition causing repeated pancreas inflammation, face a 40 to 55% lifetime risk.
Common Warning Signs Across GI Cancers
GI cancers can be tricky because their early symptoms mimic everyday digestive problems. Across the group, the symptoms worth paying attention to include:
- Unexplained weight loss, one of the most consistent red flags across all GI cancer types
- Difficulty swallowing, particularly associated with esophageal and stomach cancers
- Persistent abdominal pain that doesn’t resolve on its own
- Changes in bowel habits, including new constipation, diarrhea, or narrowing of stool
- Blood in the stool, which may appear bright red or make stools look black and tarry
- Feeling full after eating very little, a hallmark of stomach cancer
- Persistent nausea or vomiting
- Severe fatigue that doesn’t improve with rest
None of these symptoms means you have cancer. But when they’re new, persistent, and don’t have an obvious explanation, they deserve medical evaluation.
How GI Cancers Are Diagnosed
Endoscopy is the cornerstone for cancers of the upper digestive tract. For the esophagus and stomach, an upper endoscopy lets doctors visually inspect the lining and take targeted tissue samples. For colorectal cancer, colonoscopy serves the same purpose. In both cases, a biopsy, where a small piece of tissue is removed and examined under a microscope, is what confirms a cancer diagnosis.
Imaging plays a supporting role. CT scans help determine whether cancer has spread beyond the original site. For liver cancer, imaging can sometimes be diagnostic on its own, since hepatocellular carcinoma has a distinctive appearance on certain scans. Pancreatic cancer is often first spotted on a CT scan ordered to investigate unexplained symptoms like abdominal pain or weight loss.
Treatment Advances
Treatment for GI cancers typically involves some combination of surgery, chemotherapy, and radiation, depending on the cancer type and stage. In recent years, immunotherapy has changed the landscape for several GI cancers. These treatments work by helping the immune system recognize and attack cancer cells that would otherwise evade detection.
One of the most striking advances has been in colorectal cancers that have a specific genetic feature called mismatch repair deficiency. In these patients, immunotherapy combinations have shown dramatically better results than chemotherapy alone, with 72% of patients progression-free at two years compared to just 14% on chemotherapy. This has led to immunotherapy being approved as a first-line treatment for this subgroup.
For advanced liver cancer, combinations of immunotherapy with drugs that cut off a tumor’s blood supply have become standard treatment, outperforming older targeted therapies. Stomach cancers that overproduce a protein called HER2 are now treated with immunotherapy added to existing regimens, improving outcomes for a group that previously had limited options. These advances don’t apply to every patient, but they represent meaningful progress for cancers that were historically very difficult to treat.